{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:11:14Z","timestamp":1777515074543,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.diagmicrobio.2017.09.004","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T22:01:04Z","timestamp":1505772064000},"page":"294-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections"],"prefix":"10.1016","volume":"89","author":[{"given":"Julie","family":"Harting","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Wiemken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Peyrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0005","series-title":"Vibativ\u00ae [package insert]","author":"Anon","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0010","series-title":"Clinical pharmacology [database online]","author":"Anon","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0015","article-title":"IDSA clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults","author":"Berbari","year":"2015","journal-title":"CID"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2017.09.004_bb0020","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1345\/aph.1Q331","article-title":"Successful treatment of polymicrobial calcaneal osteomyelitis with telavancin, rifampin, and meropenem","volume":"46","author":"Brinkman","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0025","first-page":"151","article-title":"Impact of smoking on fracture healing and risk of complications in limb-threatening open tibia fractures","volume":"19","author":"Castillo","year":"2005","journal-title":"J Orthop Traumatol"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0030","series-title":"Performance standards for antimicrobial susceptibility testing: 24th informational supplement M100-S24","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2014"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0035","series-title":"Performance standards for antimicrobial susceptibility testing: 26th informational supplement M100-S26","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0040","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1086\/518452","article-title":"Counterpoint: Vancomycin and Staphylococcus aureus","volume":"44","author":"Derenski","year":"2007","journal-title":"CID"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0045","series-title":"Poster #307 presented at the 49th annual meeting of the infectious disease Society of America, October 2011 Boston, MA","article-title":"Outpatient parenteral antibiotic therapy (OPAT) with Telavancin: A multi-center experience","author":"Dretler","year":"2011"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2017.09.004_bb0050","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1128\/AAC.03172-14","article-title":"Revised reference broth microdilution method for testing Telavancin: Efect of MIC results and correlation with other testing methodologies","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0055","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)16727-5","article-title":"Osteomyelitis","volume":"364","author":"Lew","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the IDSA for the treatment of MRSA infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"CID"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2017.09.004_bb0065","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with MRSA bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0070","series-title":"Principles and practice in infectious diseases","author":"Mandell","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/cis966","article-title":"IDSA practice guidelines diagnosis and Management of Prosthetic Joint Infection","volume":"56","author":"Osmon","year":"2013","journal-title":"CID"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2017.09.004_bb0080","first-page":"117","article-title":"Clinical outcomes of osteomyelitis patients infected with methicillin-resistant Staphylococcus aureus USA-300 strains","volume":"41","author":"Peyrani","year":"2012","journal-title":"Am J Orthop"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2017.09.004_bb0085","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00365548.2014.995696","article-title":"Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis","volume":"47","author":"Ruggero","year":"2015","journal-title":"Infect Dis (Lond)"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2017.09.004_bb0090","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and Bactericidal activity to efficacy of Vancomycin for treatment of MRSA bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0095","series-title":"Poster #1131 presented at the 2016 IDWeek meeting, October 26\u201330, 2016, New Orleans, LA","article-title":"Real world use of Telvancin in the treatment of osteomyelitis","author":"Saravolatz","year":"2016"},{"issue":"Suppl","key":"10.1016\/j.diagmicrobio.2017.09.004_bb0100","doi-asserted-by":"crossref","first-page":"IA22S","DOI":"10.1016\/0002-9343(92)90623-J","article-title":"Smoking and wound healing","volume":"93","author":"Silverstein","year":"1992","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2017.09.004_bb0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archsurg.2012.5","article-title":"MD. Wound healing and infection in surgery: a meta analysis","volume":"147","author":"Sorenson","year":"2012","journal-title":"Arch Surg"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0110","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of Vancomycin minimum inhibitory concentration on the treatment of MRSA bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"CID"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2017.09.004_bb0115","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/cir842","article-title":"Systemic antibiotic therapy for chronic osteomyelitis in adults","volume":"54","author":"Spellburg","year":"2012","journal-title":"CID"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0120","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2334-14-289","article-title":"A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study","volume":"14","author":"Stryjewski","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2017.09.004_bb0125","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/jac\/dkg186","article-title":"Risk factors and treatment outcomes in osteomyelitis","volume":"51","author":"Tice","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00590-014-1488-y","article-title":"Smoking cessation and bone healing: optimal cessation timing","volume":"25","author":"Truntzer","year":"2015","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0135","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkr329","article-title":"Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis","author":"Twilla","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.09.004_bb0140","series-title":"Poster presented at: American Society of Health-System Pharmacists (ASHP); December 6\u201310, 2015; New Orleans, LA","article-title":"Outpatient treatment of osteomyelitis with telavancin: A retrospective chart review","author":"Xu","year":"2015"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288931730278X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288931730278X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T15:54:40Z","timestamp":1535385280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073288931730278X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S073288931730278X"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.09.004","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}